Lausanne, Switzerland - San Francisco (ots) - Funding to support BIOiSIMTM computational platform to reduce the need for animal testing by selecting compounds showing promise to cure a disease prior to research in humans Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today their co-investment in California-based start-up VeriSIM Life’s ...
San Francisco, CA (ots) - Financing led by Morpheus Ventures supports further revenue growth for the company’s next-generation AI platform, redefining the preclinical translational drug development landscape by accurately predicting and accelerating clinical outcomes VeriSIM Life (VeriSIM) www.verisimlife.com, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug ...
Schweizerischer Nationalfonds / Fonds national suisse
Bern (ots) - Research projects involving animal experiments employ a variety of methods. An SNSF-funded project on skin diseases, ulcers and cancer exemplifies this. Sabine Werner, professor of cell biology at ETH Zurich, studies how wounds heal. Knowledge of cell and tissue processes helps to better understand, diagnose and treat certain skin diseases. Here the focus is not primarily cuts and abrasions but rather wounds ...
London (ots/PRNewswire) - - Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI's AI-drug discovery platform and experimentally validated by AstraZeneca - Announcement represents the second collaboration milestone following the addition of a novel chronic kidney disease target to ...
Bologna, Italy and Huntingdon Valley, Pa. (ots/PRNewswire) - Menarini Silicon Biosystems Announces Study Results Presented at American Society of Hematology (ASH) Annual Meeting Highlighting CELLSEARCH® CMMC assay, a Non-Invasive Liquid Biopsy for the Quantification and Molecular Characterization of Circulating ...
The Hague, The Netherlands (ots/PRNewswire) - - Big Data analyses have produced novel insights that may improve the prognostication of patients with AML and CLL - These results may be used to identify high-risk patients and to make better-informed treatment choices in the future - The new data is presented at the ...
Copenhagen, Denmark (ots/PRNewswire) - - Results from ALK-sponsored REACT (REAl-world effeCTtiveness of allergy immunotherapy) study have been published in The Lancet Regional Health - Europe - REACT demonstrated the real-world effectiveness of allergy immunotherapy (AIT) - including ALK products - in allergic ...
Genomics England; Queen Mary University of London (QMUL)
London (ots/PRNewswire) - NB: SCIENCE MEDIA BRIEFING TAKING PLACE 14:00 GMT 9TH NOVEMBER 2021 - whole genome sequencing proved to be a better way to diagnose rare diseases than usual genomic testing methods - whole genome sequencing led to new rare disease diagnoses for NHS patients in some cases ending decades-long ...
London (ots/PRNewswire) - The fifth annual ranking of digital, R&D and commercial partnership innovation in global pharma The fifth annual CNS Summit Innovation Index, compiled by IDEA Pharma, sees Pfizer top the industry. Released at the CNS Summit in Boston, MA, the CNS Summit Innovation Index examines which drug makers are leveraging innovation in three spheres: clinical development which sets the stage for future ...
Lausanne, Switzerland - San Francisco (ots) - Funding to accelerate the development of Mekonos’ System on a Chip (SoC), expand commercial partnerships Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today having invested $4M inMekonos, a biotech company building the future of cell ...
Prague (ots/PRNewswire) - One of the missions that Zentiva has consistently pursued is to connect Academia and the Pharmaceutical Industry to accelerate drug development innovation and meet the unmet needs of the patients. Our company is pleased to resume the scientific exchange program as part of the ORBIS project, which was created within the largest EU grant programs HORIZON 2020, to connect European and American ...
Abcam; Nautilus Biotechnology, Inc.
Seattle and Cambridge, England (ots/PRNewswire) - Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences research tools, today announced a ...
Lausanne, Switzerland / Boston, USA (ots) - Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453, by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical ...
Schweizerischer Nationalfonds / Fonds national suisse
Bern, 14.10.2021 (ots) - The Swiss National Science Foundation (SNSF) strives consistently and continuously to improve the quality of research. A ban on animal and human experiments would massively restrict the opportunity to gain knowledge and adversely affect Switzerland as a research hub. On 13 February 2022, the Swiss electorate will vote on the initiative to ban animal and human experiments. Acceptance of the ...
Lausanne, Switzerland (ots) - Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of the 17th annual JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research –Dr. Shumpei Ishikawa and ...
Cambridge (ots/PRNewswire) - Supporting accelerated growth of R&D, manufacturing, and commercial activities with new 100,000 sq-ft state-of-the-art facility Reinforcing commitment to the region as Abcam approaches 20 years of US presence Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences reagents and tools, today announces the opening of a major new site in Waltham, MA. The new facility is a central ...
Schweizerischer Nationalfonds / Fonds national suisse
Bern (ots) - The Swiss National Science Foundation has been funding clinical studies on under-researched topics in medicine since 2016. In a first, it successfully involved representatives of patients and the public in evaluating applications. The aim of the SNSF's Investigator Initiated Clinical Trials (IICT) programme is to answer medical questions that are important to society but not a priority for industry. This ...
Brussels and Castres, France (ots/PRNewswire) - Partnership builds on complementary strengths to advance research in melanoma with a focus on Stage 2 melanoma patients European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre today announced a strategic partnership in support of patients ...
Portsmouth, N.h. (ots/PRNewswire) - Epredia, a global leader in precision cancer diagnostics, and Aiforia, a medical software company providing Artificial Intelligence (AI) based solutions for image analysis in pathology, have announced today that they have entered into a commercial distribution agreement for ...
Porto, Portugal (ots/PRNewswire) - The second edition of the BIAL Award in Biomedicine is currently underway. Worth three hundred thousand Euros, this prize is intended to reward a work with exceptional quality results and scientific relevance published in the last ten years in the broad field of biomedicine. The winner will be chosen by an independent and ...
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg. The trial showed that treatment with once-weekly semaglutide 2.4 mg led to ...
Bagsværd, Denmark (ots/PRNewswire) - Data presented at ENDO 2021 demonstrate clinically relevant weight loss, without weight regain, in people treated with semaglutide 2.4 mg vs placebo in combination with lifestyle intervention. New results from the STEP phase 3a clinical trial programme demonstrated weight loss ...
Cork, Ireland (ots/PRNewswire) - Hovione announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its Phase 2 clinical trial in 270 patients with Dry Eye caused by Meibomian Gland Dysfunction (MGD). The well controlled and representative study was conducted across 26 ...
Darmstadt, Germany (ots/PRNewswire) - MAGNIFY-MS retrospective analysis demonstrates patients develop protective antibody levels for at least six months following seasonal influenza and varicella zoster vaccines, irrespective of vaccine timing relative to MAVENCLAD dosing Initial findings from the CLOCK-MS vaccine ...
Brussels and Atlanta (ots/PRNewswire) - - Through this collaboration with Microsoft, UCB seeks to discover and develop medicines faster for people living with severe diseases in immunology and neurology - Microsoft will provide AI technology and applied scientists to work alongside UCB's scientists and data specialists, aiming to allow UCB to discover new correlations ...
European Society for Medical Oncology (ESMO)
Lausanne, Switzerland and Boston (ots/PRNewswire) - SOPHiA GENETICS, a global leader in Data-Driven Medicine, announced today a clinical research partnership initiative with the Spanish Lung Cancer Group to apply its radiomics and multimodal analysis capabilities to predict response to neoadjuvant chemoimmunotherapy ...
Tel Aviv, Israel / Lausanne, Switzerland (ots) - Nucleai (www.Nucleaimd.com), a global provider in pathology-based biomarker discovery, and Debiopharm (www.debiopharm.com), a Swiss-based biopharmaceutical company specializing in drug development, announced that they have entered into a long-term collaboration to ...
Dublin (ots/PRNewswire) - - Newly created role of Chief Business Officer to drive commercialization strategy including partnering SOLUPORE®, Avectas' non-viral cell engineering technology - Daniel Castro brings 25 years of healthcare and pharmaceutical industry experience, with a focus on licensing and deal-making - Based in Boston, MA, at the heart of a major global biotech cluster Avectas, a cell engineering company ...
ST. GALLEN, Switzerland (ots) - ForaCare Suisse AG announced the release of its antigen test, FORA COVID-19 Antigen Rapid Test, that provides fast, accurate and easy-to-interpret test results. The test can be administered by trained professionals and doesn’t rely on laboratory-processing. Approved by Swissmedic, ...